Emma Scott

Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space! rdcu.be/dAr8w @ProstateUKProfs @nubiosciences @NU_Cancer #glycotime

Coming soon! 📢 Applications for our Career Acceleration Fellowships open in March. We’re offering up to £350K over 3-4 years to support early career prostate cancer researchers to advance their career and build collaborations. 🚨Find out more here: bit.ly/3GpFeCN

I have previously attended these brilliant events for ECR’s and can’t emphasise enough how valuable they have been. A great way to keep up with the latest research, get some additional training and meet new collaborators!

Very happy to share my thoughts about the importance of allyship with @CRUKresearch. Thanks to everyone involved in our EDI @CRUK_SI who helped me shape my thoughts! news.cancerresearchuk.org/2024/05/15/the…

A comprehensive discussion about methods of detection of anti-Neu5Gc antibodies by brilliant @DiMeN_DTP student @eshutton1. It’s a joy to be involved with this project led by such a talented student @UniOfYork @nubiosciences. Congrats Esme!

@bioImaging_NCL @YorkBioimaging @NCL_IMA @nu_scan

Enjoyable session on overcoming treatment resistance - reckon we should find something else to co-host, @ethansgrumps what do you reckon? 😁 Thanks to our esteemed speakers @EScottScience Johann DeBono @royalmarsdenNHS @BevanLab @eileen_parkes @JCarrollLab 🔬#FITI24 @ProstateUK

Thrilled that the first session of the Prostate Cancer UK From Ideas to Innovation meeting is underway! @ProstateUKProfs #FITI24

Meet @BrettGarabedian #ARCSScholar @scrippsresearch who uses chemistry & protein engineering to empower our immune system against diseases, including chronic infection & cancer. Join us April 27 (4-8 pm) at our SOY event to honor our Scholars! More info: san-diego.arcsfoundation.org/2024-SOY-Celeb…

@BrettGarabedian 100% would hypothesise that they would!

📢 What role do therapies targeting glyco-immune checkpoints have in #prostatecancer? Dr Emma Scott and colleagues at @NU_Cancer and beyond show ST3Gal1 is critical to anti-tumour immunity. Congratulations publishing in @CommsBio Grab a ☕and read now: go.nature.com/3VhqSyK

@NiTriona @rebeccagarnham1 Thank you!

@rebeccagarnham1 @EScottScience Congratulations 🥳

Great to see our paper published today in communications biology which reports ST3Gal1 to synthesise Siglec-7 and Siglec-9 ligands critical to maintaining immune suppression within the prostate TIME @EScottScience🥳 nature.com/articles/s4200…

@MichaelodwyerMD @RebeccaGarnham @Palleon_Pharma @Glycotime @CarolynBertozzi @aideenryan1 Thank you Michael! Super important that we pursue this to improve treatment options for patients

@NatashaHepburn4 Thanks Natasha!

Huge congrats 👏

@ahmadurology @ProstateUKProfs @nubiosciences @NU_Cancer Thanks Imran - hope things are going well!

Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space! rdcu.be/dAr8w @ProstateUKProfs @nubiosciences @NU_Cancer #glycotime

@salva_iborra @rebeccagarnham1 Thank you!

@EScottScience @rebeccagarnham1 Really interesting, congrats!

@KirstCampbe11 @ProstateUKProfs @nubiosciences @NU_Cancer @rebeccagarnham1 Thanks Kirsteen - hope you’re getting on okay!

@EScottScience @ProstateUKProfs @nubiosciences @NU_Cancer Excellent work @EScottScience @rebeccagarnham1 and team, congratulations!

@AsmaAhmedHassan @ProstateUKProfs @nubiosciences @NU_Cancer Thanks Asma! Looking forward to hopefully catching up at the PCUK meeting soon!

@EScottScience @ProstateUKProfs @nubiosciences @NU_Cancer Congratulations Emma! Great work!

@HayleyJLuxton @rebeccagarnham1 Thanks Hayley!

@EScottScience @rebeccagarnham1 Congratulations @EScottScience and @rebeccagarnham1 - such a star-studded line-up of authors 🤩 Looking forward to grabbing a coffee and having a read!